---
layout: post
title: "EFIRM for Lung Cancer: Latest Update"
author: "EZLife Bio"
---

Three exciting new papers have been published on the EFIRM technology, again showing EFIRM's immense viability as a tool for liquid biopsy of cancer. 

## EFIRM for Monitoring of Lung Cancer Mutations
This first new paper was led by Dr. Ning Li in collaboration with the National Cancer Institute, detailing the usage of EFIRM to perform monitoring of the 
<img src="https://raw.githubusercontent.com/ezlifebio/ezlifebio.github.io/master/img/news/2020-07-24-01.png">


## EFIRM for detecting Ultra-Short Circulating Tumor DNA of Non-Small Cell Lung Cancer (NSCLC) Patients 
<img src="https://raw.githubusercontent.com/ezlifebio/ezlifebio.github.io/master/img/news/2020-07-24-02.png">


# EFIRM for application as a clinical assay

[1] https://www.frontiersin.org/articles/10.3389/fonc.2020.01240/full
[2] https://www.mdpi.com/2072-6694/12/8/2041
[3] https://jmd.amjpathol.org/article/S1525-1578(20)30350-0/abstract
